Lupin (LUPIN.NS) Stock Price
Lupin Price
Over the last 19 years Lupin grew revenue by 14.9% annually, reaching 279.58 B INR. Earnings per share have grown at 16.2% per year over the last 19 years. For Lupin, the net margin of 19.1% is up versus -9.3% a few years ago. At today's price the dividend yield works out to roughly 0.62%. The payout ratio is around 26% of earnings. The dividend has grown at 14.0% per year over the past 19 years. The consensus 12-month price target for Lupin is 2,397.00 INR, about 22.9% above where the stock trades today. Of 43 analysts, 29 rate the stock a buy — an overall Buy consensus.
Lupin stock price
Lupin business model & stock analysis
Frequently asked questions about Lupin
The business model of Lupin Ltd revolves around the pharmaceutical industry. As a leading global pharmaceutical company, Lupin focuses on developing, manufacturing, and marketing a diverse range of generic and branded pharmaceutical products. With a strong emphasis on research and development, Lupin strives to bring innovative solutions and affordable medications to patients worldwide. The company's business model includes a global presence, strategic partnerships, and a commitment to quality and compliance. Lupin Ltd's extensive product portfolio covers various therapeutic areas, including cardiovascular, central nervous system, dermatology, and respiratory, among others, catering to the healthcare needs of millions of people.
Lupin Ltd is primarily active in the pharmaceutical industry.
The main competitors of Lupin Ltd in the market include companies like Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Cipla Ltd., and Torrent Pharmaceuticals Ltd.
Lupin Ltd. is a renowned pharmaceutical company with a rich history and background. Established in 1968, Lupin has emerged as a global leader in the pharmaceutical industry. The company's relentless focus on innovation and research has paved the way for groundbreaking drug discoveries and cutting-edge formulations. Lupin operates through various business segments, catering to a wide range of therapeutic areas including cardiovascular, respiratory, central nervous system, and anti-infective. With a strong global presence across multiple countries, Lupin has earned a stellar reputation for delivering affordable and high-quality healthcare solutions. Over the years, Lupin Ltd. has consistently showcased its commitment to improving global health outcomes with its diverse portfolio of pharmaceutical products.
Lupin Ltd has accomplished several significant milestones throughout its history. One of the major achievements was the company's successful listing on the Bombay Stock Exchange and the National Stock Exchange of India. Lupin also made notable achievements in the global pharmaceutical industry by receiving various regulatory approvals for its high-quality and affordable generic medications. Furthermore, Lupin has expanded its operations globally by establishing a strong presence in key markets like the United States, Europe, Japan, and other emerging markets. These achievements have reinforced Lupin's position as a leading global pharmaceutical company, delivering innovative healthcare solutions to patients worldwide.
Lupin Ltd, a renowned pharmaceutical company, has a significant global presence. The company primarily operates in various countries and regions, including but not limited to India, United States, Europe, Japan, and South Africa. With its strong foothold in these markets, Lupin Ltd has established itself as a leading player in the pharmaceutical industry.
Lupin Ltd is known for upholding strong values and a robust corporate philosophy. Guided by their core principles, Lupin strives for excellence, integrity, and transparency in all their operations. The company firmly believes in providing high-quality pharmaceutical products that improve the lives of patients globally. With a focus on innovation, Lupin continually invests in research and development to bring cutting-edge healthcare solutions to the market. Dedicated to social responsibility, Lupin actively engages in initiatives for the betterment of society, promoting sustainable development and fostering inclusive growth. Through their unwavering commitment to quality, ethics, and social welfare, Lupin Ltd emerges as an industry leader, delivering value to various stakeholders and ensuring a positive impact on the healthcare sector.
Analysts currently set an average price target of 2,338.63 INR for the Lupin stock (median: 2,397.00 INR), implying +19.9 % versus the latest price. The consensus is based on 43 analyst ratings.
43 analysts currently rate the Lupin stock: 29 recommend buying, 11 holding and 3 selling.
Converted at the current exchange rate, the Lupin share trades at 18.00 EUR (1,950.70 INR).
The Lupin share (LUPIN.NS) is listed on 2 stock exchanges, including: NSE (Indien) (LUPIN.NS).
Lupin Ltd is a leading pharmaceutical company based in India. The company's business model is based on the production and distribution of pharmaceutical products and generic medications worldwide. Lupin operates in three business segments: generics, branded products, and carbamazepine. The generics segment is the core of Lupin's business model, offering a wide range of cost-effective alternatives to expensive brand-name medications. Lupin also produces branded products, primarily sold in India, including antibiotics, diabetes medications, and hormonal treatments. The carbamazepine segment specializes in the production of antiepileptic drugs and is a significant part of Lupin's business model. The company also emphasizes research and development, investing a significant percentage of its revenue in the development of new drugs. Lupin has established a global distribution network, with subsidiaries in the US, Europe, and Japan, as well as distribution partners in other countries. The company has made strategic acquisitions and mergers to strengthen its presence in different regions, such as the acquisition of Gavis in 2016 to expand its generics business in the US. Overall, Lupin's business model revolves around the production and distribution of pharmaceutical products and generics worldwide, with a strong emphasis on research and development and a global distribution network.
The revenue of Lupin is 279.58 B INR. This figure is based on current financial data and reflects the company's business performance.
The profit of Lupin is 53.33 B INR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Lupin is currently 16.76. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lupin stock.
The price-to-sales ratio (P/S) of Lupin is currently 3.20. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lupin stock.
The Eulerpool Quality Score for Lupin is 5/10.
The ISIN of Lupin is INE326A01037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Lupin is LUPIN.NS. The ticker symbol is used to trade Lupin shares on the stock exchange.
Lupin stock
Lupin Peer Group
Lupin Ticker
Lupin FIGI
All fundamentals and in-depth analysis of Lupin
Our stock analysis for Lupin stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lupin. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.